CNS biotech Rapport snags a CFO veteran from Karuna; Bristol Myers’ new CEO to chair the board next year
Troy Ignelzi happened into the biopharma world. He had dropped his sole college science course to go play racquetball with his then-girlfriend (now wife of 32 years).
But, years later, while working on economic development in the Kalamazoo, MI area, he helped support local biotech companies built by the scientists whom Pfizer was letting go in the late 1990s as part of an R&D shuffle. He hopped over to Eli Lilly in the early 2000s and has since helped multiple drug developers raise, collectively, more than $4 billion, including a few IPOs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
